

# Cytochromes P450, Oxygen, and Evolution

David F.V. Lewis\* and Grainn  Sheridan

School of Biomedical and Life Sciences, University of Surrey,  
Guildford, Surrey, GU2 7XH

**The role of the cytochrome P450 superfamily of heme-thiolate enzymes in oxidative metabolism is discussed in the context of evolutionary development. Concordances between the rise in atmospheric oxygen content, elaboration of the P450 phylogenetic tree and the accepted timescale for the emergence of animal phyla are described. The unique ability of the P450 monooxygenase system to activate molecular oxygen via the consecutive input of two reducing equivalents is explored, such that the possibility of oxygen radical generation and its toxic consequences can be explained in mechanistic terms, together with an appreciation of the ways in which this oxygen activating ability has been utilized by evolving biological systems in their adaptation to an increasing atmospheric oxygen concentration over the past two billion years.**

**KEY WORDS:** cytochrome P450, oxygen, free radicals, evolution, oxidative metabolism, reactive oxygen species

**DOMAINS:** metabolism, molecular evolution, biochemistry

## INTRODUCTION

The cytochromes P450 (CYP) constitute a superfamily of enzymes, present in every biological kingdom<sup>1</sup>, which are involved in the oxidative metabolism of a vast number of chemicals, both endogenous and exogenous, encompassing diverse structural classes and functionality of catalytic reactions<sup>2,3</sup>.

P450s are now classified as heme-thiolate enzymes<sup>4</sup> rather than cytochromes which are redox components in various cellular electron transfer pathways, such as the cytochromes a, b, and c, although all of these enzymes are hemoproteins because they all contain a heme prosthetic group. The redox potentials of hemoproteins vary considerably due to the influ-

ence of the protein environment and the particular heme ligands involved<sup>5</sup>. This is illustrated in Table 1 where the iron redox potentials ( $E^\circ$  values) of various hemoproteins are compared. It can be appreciated from Table 1 that P450s possess relatively high negative iron redox potentials in comparison with other hemoproteins. This is due to the characteristic cysteine ligand in P450 and also to the significant amount of heme exposed to the environment at the distal face where, in the absence of substrate, there is a bound water molecule coordinating the iron by occupying the distal heme site<sup>6</sup>. The binding of a substrate to P450 has a profound effect on the redox potential, together with other physicochemical characteristics, which triggers the entire catalytic cycle of the enzyme (*vide infra*).

As far as enzymes in general are concerned, however, the P450s can be regarded as being exceptional in their phenomenal substrate diversity, because most enzymes usually only accept substrates from a well-defined structural class<sup>7</sup>. In order to appreciate why this is so, it will be necessary to consider, first of all, the development of the P450 superfamily in the context of biological evolution over the past 3500 million years.

## P450 ENZYMES AND EVOLUTION

Over 1200 individual P450s have had their protein sequences determined to date<sup>1</sup> and these are classified by gene family and subfamily using a numerical system to designate the P450 family, together with an alphanumeric symbol for the subfamily and individual protein. This system of classification is based on percentage sequence homology between P450s and, therefore, facilitates the construction of a phylogenetic tree for the enzyme superfamily which can be related to the development of biological species over time on the basis of specific mutation rates for the P450 genes<sup>8,9,10</sup>. Fig. 1 shows that the evolution of the P450 superfamily mirrors the generally ac-

\* Corresponding Author: Tel: +44 (0)1483 876477;  
Fax: +44 (0)1483 300803; email: d.lewis@surrey.ac.uk  
  2001 with author.

**TABLE 1**  
**Iron Redox Potentials for Hemoproteins**

Hemoprotein	% Heme Exposure	$E^0_{\text{Fe}^{3+}/\text{Fe}^{2+}}$ (mV)	Heme Ligands
Cytochrome $c_2$	6	320	Met, His
Cytochrome $c$	4	260	Met, His
Cytochrome $c_{550}$	5	250	Met, His
Hemoglobin $\alpha$	14	113	His, His
Hemoglobin $\beta$	20	53	His, His
Myoglobin	18	47	His, His
Cytochrome $b_5$	23	20	His, His
Cytochrome P450	~40	-400	Cys, $\text{H}_2\text{O}$

*Abbreviations:* Met = methionine; His = histidine; Cys = cysteine.

*Note:* The relationship between redox potential ( $E^0$ ) and % heme exposure to the aqueous environment is as follows:

$$E^0_{\text{Fe}^{3+}/\text{Fe}^{2+}} \text{ (mV)} = 14.94\% \text{ exposure} + 343.88 \quad n = 7; s = 37.36; R = 0.96; F = 46.0 \quad (\pm 1.95)$$

This expression was derived for the first 7 proteins in the above table using the data reported by Stellwagen<sup>78</sup> and this was used to estimate the % heme exposure in P450<sup>2</sup>. The redox potentials in P450s vary depending on the isoform and whether there is a bound substrate, which lowers the redox potential. For example, camphor binding to P450<sub>cam</sub> (CYP101) is accompanied by a change in  $E^0$  from -313 to -173 mV<sup>52</sup>. According to the above equation, substrate binding to P450<sub>cam</sub> can be expected to reduce the heme exposure from 44 to 35%<sup>2</sup>.

cepted timescale for the development of life on Earth<sup>2,11</sup>, whereas Fig. 2 provides an example of a phylogenetic tree for selected P450s in various animal species using the UPGMA\* approach (see legend to Fig. 2 for details). There are certain correspondences (see Table 2) between specific evolutionary events and the elaboration of the P450 phylogenetic tree which support this viewpoint<sup>2,8</sup>. In particular, it is now currently accepted that around 2,000 million years ago the earth's atmosphere started to become oxygenated<sup>12</sup>, leading to the emergence of eukaryotic species distinct from the original prokaryotic biota<sup>13</sup>. Although it is thought that the ancestral P450 gene may have arisen in a prokaryotic species about 3,500 million years ago<sup>14</sup> when the terrestrial atmosphere was reducing in nature, there is likely to have been sufficient oxygen available for P450-mediated catalytic transformations of organic carbon sources in bacterial systems. However, with the advent of free oxygen in the atmosphere<sup>15,16</sup> produced from photosynthetic bacteria, unicellular eukaryotic species developed by the fusion of prokaryotes (which became cell organelles) and their encapsulation in a protective cell membrane<sup>17</sup>. It is possible that the increased oxygen concentration may have been the driving force for this major biologi-

cal development<sup>18</sup>, because the formation of eukaryotic organisms would have afforded some protection from the potentially damaging effects of reactive oxygen species (ROS). Indeed, the development of enzyme systems such as catalase and superoxide dismutase<sup>19</sup> to deal with ROS, like peroxide and superoxide, would have enabled the catalytic functions of P450s to diversify without the cytotoxic side-effects of uncoupled dioxygen reduction. Consequently, increasing oxygenation of the atmosphere facilitated the evolution of specific P450 isozymes which could be 'tailored' to recognize certain structural classes of chemicals that possessed the potential for important endogenous roles in the newly emerging eukaryotes<sup>11</sup>.

It is generally accepted that by 1000 million years ago animal-plant divergence had occurred together with the development of sexual reproduction<sup>17</sup>. It is possible that branching of the eukaryote stem of the P450 phylogenetic tree may have taken place during this period, where bifurcation into mitochondrial and microsomal P450s would have coincided with the requirement for steroid hormone biosynthesis from cholesterol in order to regulate sexual characteristics<sup>3</sup>. However, the situation is likely to have been more complex than is

\* Unweighted Pair Group Method of Analysis.





FIGURE 1. An abbreviated version of the P450 phylogenetic tree (adapted from References 2 and 11) using data compiled from a number of sources (see text for details).



**FIGURE 2.** Phylogenetic tree of cytochrome P450 protein sequences from families CYP1, CYP2 and CYP3 inferred using the UPGMA tree drawing algorithm with Kimura calculated distances. Protein sequences were aligned using ClustalW with manual readjustments based on known secondary structure conformation. Alignments of P450 protein sequences have been reported previously<sup>2,11</sup>.

**TABLE 2**  
**Concordances between Evolution and P450 Development**

MYA	Biological Development	P450 Superfamily Divergences
2000	Eukaryotic cells	Prokaryotic-Eukaryotic CYPs
1000	Plant-animal divergence	Mitochondrial-Microsomal CYPs
800	Ediacaran biota	CYP3 and 4 split from other microsomal CYPs
650	Divergence of animalia	CYP3 and CYP4 divergence
550	Animal phyla radiate	CYP1 and 2 diverge from CYP17 and 21
470	Invertebrates	CYP1 and CYP2 diverge
450	Land colonization	CYP17 and CYP21 diverge
370	Amphibia	CYP2D diverges from CYP2
300	Bird-mammal divergence	CYP2D radiates
250	Reptilia	Divergence of CYP2 family
230	Mammalia	CYP2A and CYP2B diverge, CYP2C and CYP2E diverge
120	Placental mammals	CYP1A1 and CYP1A2 diverge
80	Mammalian radiation	Speciation of P450 families and subfamilies

MYA = million years ago

Adapted from Reference 11.

apparent from phylogenetic comparisons because of the probable prokaryotic origins of eukaryotic cell organelles, such as mitochondria<sup>20</sup>. Moreover, there is evidence to suggest that animal species may have increased their body size in order to minimize the mutagenic effects of ROS<sup>21</sup> with mitochondria representing the major organelle associated with oxygen consumption.


Elaboration of the animal phylogeny around 800 million years ago, as evidenced by the Ediacaran biota fossil data, appears to correspond with a further branching of the P450 tree where the CYP3 and CYP4 families split from the main microsomal P450 limb<sup>22</sup>. The functions of these P450s lie in steroid and fatty acid metabolism, respectively, and as such play important roles in the regulation of steroid hormones, prostaglandins and poly-unsaturated fatty acids, such as arachidonic acid, for example<sup>23,24</sup>.

The steady increase in atmospheric oxygen levels, paralleling the general rise in animal species over the last 2 billion years<sup>25,26</sup>, should be set, however, against a backdrop of terrestrial cycles which probably contributed to extinction events over geological time<sup>27</sup>. Radiation of the animal phyla at around 550 million years ago, during what is termed the Cambrian 'explosion', followed the divergence of animalia about 650 million years ago; concordances with the P450 tree development indicate that, initially, the CYP3 and CYP4 families separated, with the divergence of CYP1 and CYP2 from the remaining steroidogenic P450 families, CYP17 and CYP21,

occurring in the Cambrian period<sup>22</sup>. In this way, it would appear that the P450s primarily associated with exogenous metabolism (CYP1, CYP2 and CYP3) separated from those involved in endogenous compound metabolism (CYP4, CYP11, CYP17 and CYP21) over a period of 500 million years, from 1000 million years ago to about 500 million years ago, at a time (termed the Neoproterozoic era) where animal species underwent significant evolutionary development<sup>27</sup>.

In addition to the concurrent rise in the oxygen content of the atmosphere, it is possible that global plate tectonic changes, such as opening of the Iapetus ocean (circa 700 million years ago) may have played a part in biological evolution by contributing to major extinction events<sup>28</sup>. In fact, there is some degree of correlation between the supercontinental cycle and disappearance of certain species, via its effect on long-term eustatic sea level fluctuations<sup>29</sup>. This is also apparent in the Mesozoic and Cenozoic eras, where it has been argued<sup>30</sup> that continental fission and fusion may have led to the ordinal divergence of avian and mammalian species.

However, a major concordance between the microsomal P450 branching and animal evolutionary development has been documented<sup>8</sup> which corresponds to the Devonian period when animals began to colonize land<sup>27</sup>. By an example of coevolution which has been termed animal-plant 'warfare', it would appear that animal species developed specific xenobiotic-metabolizing P450s to detoxify poisonous plant products which had been biosynthesized by various plant



**FIGURE 3.** Increase in atmospheric oxygenation over the past 3,500 million years plotted on a logarithmic scale (adapted from Reference 2 and based on data compiled by Cloud<sup>12</sup>).

species to deter animal predators<sup>8</sup>. It is interesting to note that the Devonian period corresponds to the time when the oxygen content of the atmosphere rose dramatically, probably reaching about 50% of the present level around 397 million years ago<sup>12</sup>. Fig. 3 shows that if the relevant data are plotted using a logarithmic time axis, the increase in percentage oxygen concentration of the atmosphere exhibits a sigmoidal relationship over a 2000 million year period<sup>2,11</sup>.

According to estimations based on sequence Homology and generally accepted mutation rates, the divergence of CYP1 from CYP2 took place around 470 million years ago during the development of invertebrates, whereas the emergence of amphibia and land colonization (about 400 million years before present) corresponds with initial branching of the CYP2 family where CYP2D divergence may have represented a response to the evolutionary pressures posed by toxic plant products<sup>11</sup>. As the preferred substrates of CYP2D possess basic nitrogen atoms, and many of these are ligands (antagonists or agonists) of G-protein-coupled receptors associated with the transduction of neurological signals, it seems likely that initial plant toxins may have acted on the central nervous systems of predatory species who, in turn, would have required an enzyme system capable of detoxifying such hazardous chemicals. Consequently, it is possible to rationalize that the first bifurcation of the CYP2 family probably would have

been that of the CYP2D subfamily, as indicated by sequence comparisons<sup>8</sup>.

The generally accepted times for the divergence of avian and mammalian species at about 300 million years ago, radiation of reptiles around 250 million years ago, and further mammalian development 230 million years before present correspond with the divergence of the CYP2 family into the five major subfamilies, CYP2A through to CYP2E<sup>31</sup>. This significant elaboration of the CYP2 family may represent an evolutionary response to other plant toxins, such as flavonoids and alkaloids, although there is emerging evidence for endogenous roles of various CYP2 subfamilies. For example, enzymes of the CYP2A, CYP2B, and CYP2C subfamilies exhibit significant sex differences in steroid metabolism for experimental rodent species, such that these may have a function in regulating steroid hormone levels<sup>32</sup>. Moreover, the CYP2D and CYP2E subfamilies have been implicated in neurotransmitter metabolism<sup>33</sup> and in gluconeogenesis, respectively<sup>34</sup>.

Placental mammals developed around 120 million years ago; this coincides with the likely divergence between two related P450s in the CYP1 family, namely, CYP1A1 and CYP1A2<sup>35</sup>. It is possible that the CYP1A2 isozyme is required for the regulation of oestrus, as it has been established<sup>36</sup> that CYP1A2 levels are modulated by the menstrual cycle. Consequently, placental mammals would have presumably required

CYP1A2 to vary the levels of oestrogens at certain stages in the female monthly cycle. By 80 million years ago, the mammalian radiation is coincident<sup>11</sup> with extensive speciation of mammalian P450 genes, which are likely to have formed orthologous proteins during this period<sup>37</sup> when most modern mammalian species evolved, including primates<sup>38</sup>.


One of the intriguing aspects of primate development in the context of P450 evolution lies in the finding that there are substantial differences in the hepatic P450 complement of New World and Old World primate species. Essentially, the New World monkeys possess significant levels of CYP1A2 but little or no CYP2A6, whereas the opposite is found for Old World primates<sup>39</sup>. *Homo sapiens*, however, possesses both CYP1A2 and CYP2A6 in approximately equal amounts. The reasons for these changes may lie in continental drift followed by altered dietary habits as a consequence of different habitats<sup>40</sup>. It is possible that, during the time of separation between the South American and African continents over 100 million years ago, two pro-simian populations became geographically isolated such that these effectively separated species evolved differently as a response to habitat and food sources<sup>11</sup>. This would have led to substantial differences between CYP1A2 and CYP2A6 levels in New and Old World primates because the former have omnivorous dietary habits, whereas the latter are essentially herbivores<sup>41</sup>. In this respect, it is important to recognize that CYP2A6 metabolizes many plant flavonoids and CYP1A2 is involved in the oxidative metabolism of nitrogenous compounds, such as heterocyclic amines and amides<sup>42</sup>. Mankind may have originally been herbivorous but, at some stage in their development, became more carnivorous, with the consumption of cooked meat representing a relatively recent dietary practice<sup>43</sup>. It is logical, therefore, that *Homo sapiens* now possesses roughly equivalent percentages of CYP1A2 and CYP2A6, which would be consistent with our current dietary preferences.

As far as drug metabolism, in particular, is concerned, it has been well established that human ethnogeographical populations exhibit genetic polymorphisms towards certain classes of drug substrates, many of which correspond to point mutations in P450 genes<sup>44</sup>. Consequently, small percentages of different human populations show impaired metabolic competence for an increasing number of pharmaceutical agents which are either CYP2D6 or CYP2C19 specific<sup>42</sup>. The reasons for these genetic polymorphisms are, as yet, unknown but may be a natural consequence of the genetic diversity encountered in human populations<sup>8</sup> possibly associated with dietary differences<sup>44</sup>, whereas other animal species tend to be more genetically pure, although the strain differences encountered in some experimental rodent species could represent an analogy with the known genetic polymorphism exhibited by human populations.

A possible reason for mankind possessing a complement of P450 isozymes capable of metabolizing the majority of known pharmaceutical agents may lie in the elaborations of the P450 phylogenetic tree which took place over the last 400 million years<sup>11</sup>. Most modern drugs have been designed on templates afforded by existing plant products, and this is also probably true of the various agrochemicals to which we are exposed. Consequently, *Homo sapiens* would be able to utilize the P450 system of xenobiotic metabolizing enzymes in the oxidative metabolism of pharmaceutical agents in current use, despite the fact that these isozymes had previously been developed to detoxify plant chemicals<sup>8</sup>. In order to understand the way in which P450s are able to metabolize such a wide variety of chemicals, it is important to consider their properties and the typical P450 enzyme's catalytic cycle.

## PROPERTIES AND CHARACTERISTICS OF P450S AND THEIR SUBSTRATES

The average molecular mass of P450 enzymes is around 50kDa and the protein consists of polypeptide chain of about 500 amino acid residues (reviewed in Reference 2). All P450s contain a heme prosthetic group with a thiolate fifth ligand from an invariant cysteine residue (proximal to the heme face) which forms part of a high conserved 10-residue signature motif identifiable in every P450 sequence known<sup>1</sup>. The heme moiety, with its cysteine thiolate ligand, is able to bind (and, subsequently, activate) oxygen by splitting the diatomic molecule into water (via protonation) and a bare oxygen atom<sup>4</sup>. This highly reactive single oxygen atom combines with a bound organic substrate which is held in position by key amino acid residues within the enzyme's active site at the distal heme face, such that oxygenation at a specific region of the substrate molecule occurs<sup>4</sup>. Due to the fact that a single oxygen is inserted into the substrate, the P450 enzyme is sometimes referred to as a mono-oxygenase, and the mono-oxygenated product (i.e., metabolite) of the reaction is usually a hydroxy compound (alcohol or phenol), epoxide, N-oxide (or S-oxide), or a hydroxylamine<sup>45</sup>, although other metabolites are known<sup>46,47</sup>. For a hydrocarbon substrate, RH, it is possible to represent the general P450-catalyzed reaction<sup>3</sup> as follows:



where the two reducing equivalents ( $2\text{H}^+$ ,  $2\text{e}^-$ ) are supplied by NADPH (or NADH) and the reduction is mediated by either an FAD-containing flavoprotein and iron-sulphur redoxin or an FAD- and FMN-containing flavoprotein oxidoreductase, depending on the type of P450 system<sup>48</sup>.

The substrates of P450 isozymes, which may be in excess of 200,000 chemicals<sup>46</sup>, comprise virtually every class of organic compound, including polyaromatic hydrocarbons (e.g., benzo(a)pyrene), steroids (e.g., testosterone), nitrosamines (e.g., DMN), alkenes (e.g., butadiene), ketones (e.g., acetone), alcohols (e.g., ethanol), nitro compounds (e.g., p-nitrophenol), amides (e.g., 2-acetylaminofluorene), barbiturates (e.g., phenobarbital), heterocyclic compounds (e.g., caffeine), haloethanes (e.g., chloroform), alkaloids (e.g., nicotine), ethers (e.g., aflatoxin), organophosphates (e.g., parathion), amines (e.g., benzphetamine), carboxylic acids (e.g., lauric acid), organochlorine pesticides (e.g., DDT), azo compounds (e.g., sulphasalazine), esters (e.g., MEHP), benzodiazepines (e.g., diazepam) and  $\beta$ -blockers (e.g., propranolol). Table 3 summarizes the substrate specificity exhibited, for example, by human liver P450s<sup>42</sup>.

Due to the enormous structural diversity of their substrates (in stark contrast with those of other enzymes), P450s are sometimes referred to as mixed function oxidases because of the extraordinary variety of functional groups which may be present in their substrate molecules<sup>4</sup>. The reasons for such a vast number of potential substrate entities lie in the relatively large number of P450 enzymes, even within a single species, and the distinct pattern of amino acid residues in the active sites of some P450s which enable contact with many different kinds of substrates<sup>2</sup>. There is, however, an important distinction between those P450s that are involved in endogenous compound metabolism and those which metabolize xenobiotic chemicals. In general, the P450s responsible for

the metabolism of endogenous substrates such as steroids, prostaglandins, eicosanoids, and fatty acids possess a well-defined substrate specificity for each enzyme which, in some cases, is specific for one compound only<sup>3</sup>. On the other hand, those P450s which play a major role in the metabolism of xenobiotics exhibit relatively wide substrate specificities, although there are certain structural determinants that are able to define whether a given chemical is likely to be a substrate for one P450 or another<sup>49</sup>. There are also many examples where a chemical is metabolized by more than one P450, but at different sites on the substrate molecule; as is the case with the anti-ulcer drug omeprazole, which is metabolized by both CYP3A4 (S-oxidation) and CYP2C19 (5-methyl hydroxylation) in human liver<sup>42</sup>.

For P450s that metabolize foreign chemicals, it is possible for enzymic activation to occur leading to the formation of reactive intermediates<sup>47</sup> which are potentially toxic; some P450s have been implicated in the metabolic activation of many known carcinogens such as benzene, benzo(a)pyrene,  $\beta$ -naphthylamine, cyclophosphamide, butadiene, dialkylnitrosamines, aflatoxin, and several heterocyclic amines formed during the pyrolysis of meat proteins<sup>50</sup>. In fact, most pro-carcinogen activation is mediated by P450s and, primarily, it appears that enzymes of the CYP1A and CYP2E subfamilies are mainly responsible for the production of genotoxic reactive species in both experimental animals and man, following the exposure/ingestion of potentially carcinogenic chemicals<sup>3</sup>. However, the remaining xenobiotic-metabolizing P450s in mammalian liver are generally associated with the detoxica-

**TABLE 3**  
**Human Xenobiotic-Metabolizing P450s: Substrates, Inducers, and Inhibitors<sup>42</sup>**

CYP	Substrate	Specific Reaction	Inhibitors	Inducers
1A1	7-Ethoxyresorufin	O-Deethylation	9-Hydroxyellipticine	TCDD
1A2	Caffeine	N <sub>3</sub> -Demethylation	Furaphylline	Heterocyclic amines
1B1	17 $\beta$ -Estradiol	4-Hydroxylation	Propofol	Indolocarbazole
2A6	Coumarin	7-Hydroxylation	Pilocarpine	Dexamethasone
2B6	7-Ethoxy 4-trifluoro-methyl coumarin	O-Deethylation	Orphenadrine	Phenobarbital
2C9	Tolbutamide	4-Methyl hydroxylation	Sulfaphenazole	Barbiturates
2C19	Omeprazole	5-Methyl hydroxylation	Fluconazole	Barbiturates
2D6	Debrisoquine	4'-Hydroxylation	Quinidine	None known
2E1	4-Nitrophenol	2-Hydroxylation	4-Methyl pyrazole	Ethanol
3A4	Nifedipine	N-Oxidation	Ketoconazole	Dexamethasone

TCDD = 2,3,7,8-tetrachlorodibenzo-p-dioxin.

tion of exogenous compounds<sup>50</sup>. Consequently, P450s can be regarded as a ‘double-edged sword’ with respect to the metabolism of foreign chemicals, being able to detoxify or activate depending on the nature of compound and the type of P450 involved in oxygenating the substrate molecule. To explore this aspect further, it will be necessary to review the operation of P450’s catalytic pathway and consider the way in which oxygen is activated.


## THE P450 CATALYTIC CYCLE AND OXYGEN ACTIVATION

The proximal sulphur ligand from an invariant cysteine residue in its thiolate state brings about activation of the heme-bound oxygen molecule, which binds to P450 at the distal heme face<sup>51</sup>. Other hemoproteins, such as hemoglobin and myoglobin, are able to bind oxygen similarly to that of P450, but activation does not occur because these oxygen binding carrier proteins possess a proximal histidine residue instead of cysteinate as encountered in P450<sup>51</sup>. The difference in effect between the oxygen carrier proteins and P450 is related to the Fe<sup>3+</sup>/Fe<sup>2+</sup> redox potential of the heme iron which, in the case of P450, is substantially more negative than other hemoproteins<sup>5</sup>. Moreover, substrate binding to P450 has a marked effect on the iron redox potential, together with producing a significant modulation of iron spin-state equilibrium<sup>52</sup>.

The P450 reaction involves a controlled activation of oxygen by the consecutive input of two electrons from NADPH (or NADH) via intermediary redox partners, which differ between mitochondrial, microsomal, and bacterial P450 systems<sup>48</sup>. Most bacterial P450s (except some of those in the CYP102 family) utilize an iron sulphur redoxin to mediate electron transfer from an NADH-dependent FAD-containing flavoprotein reductase<sup>53</sup>. Mitochondrial P450s in animals resemble the bacterial systems in containing an electron transport chain consisting of an NADH-specific FAD-dependent oxidoreductase and an iron sulphur redoxin which transfers electrons to P450<sup>48</sup>. This striking similarity between prokaryotic and animal mitochondrial P450 systems adds weight to the view that mitochondria may have originated from bacterial species<sup>54,55</sup>. In contrast, microsomal P450s utilize an FAD- and FMN-containing oxidoreductase flavoprotein for transferring electrons from NADPH<sup>56</sup>. One of the few known bacterial P450s that possesses a similar system is CYP102 from *Bacillus megaterium*, where the reductase moiety is fused with the hemoprotein domain<sup>57</sup>. Although the prokaryotic origins of mitochondrial P450s can be regarded as hypothetical<sup>17</sup>, there is compelling evidence from mRNA comparison that support the theory<sup>54,55</sup>.

In order for the P450-mediated reaction to take place it is necessary for there to be two consecutive reduction steps, whereby the electronic state of bound dioxygen is succes-

sively altered by the addition of two electrons from reductant (NADH or NADPH), a process which is carried out by a P450-bound redox partner (i.e., redoxin or flavoprotein reductase). In order for this two-stage reduction to occur, however, the dioxygen molecule is required to constitute the terminal species of an electron transfer gradient<sup>45</sup> formed by the sequential stages outlined below:



where the arrow (→) represents the transfer of a single electron.

Consequently, the redox potentials of each component in the electron transport pathway should become less negative as one proceeds down the electron transfer chain<sup>45</sup>. Table 4 shows the standard redox potentials (E° values) for the participant species in the bacterial P450<sub>cam</sub> (CYP101) system, together with those of the relevant dioxygen couples<sup>2</sup>. This table indicates that, in its resting state, P450<sub>cam</sub> has a too highly negative redox potential (-303 mV) to become reduced by its redox partner, putidaredoxin. However, when the substrate camphor binds to P450<sub>cam</sub>, there is a dramatic lowering of the redox potential (i.e., it becomes less negative) which becomes -173 mV in the substrate-bound enzyme<sup>52</sup>. In this way, substrate binding is able to control the P450 catalytic cycle by facilitating reduction of the enzyme<sup>2,45</sup>.

Additionally, the iron spin-state equilibrium is significantly altered when the substrates binds, and it appears that there is substantial coupling between spin and redox equilibria in both

**TABLE 4**  
**Redox Potentials (E°) in the P450<sub>cam</sub> System<sup>2</sup>**

Species	E° (mV)
NADH	-320
FAD	-290
Pdx	-240
P450 <sub>cam</sub>	-303
P450 <sub>cam</sub> + substrate	-173
O <sub>2</sub> /O <sub>2</sub> <sup>-</sup>	-160
O <sub>2</sub> <sup>-</sup> /O <sub>2</sub> H	-100

**Abbreviations:** NADH = nicotinamide adenine dinucleotide; FAD = flavin adenine dinucleotide; Pdx = putidaredoxin; P450<sub>cam</sub> = camphor 5-exo mono-oxygenase in *pseudomonas putida*.

the bacterial and microsomal P450 systems<sup>58</sup>. Table 5 indicates that substrate binding modulates the iron spin-state equilibrium with concomitant lowering of redox potential in P450<sub>cam</sub> (CYP101) and also in rat liver microsomal P450, where there is strong correlation ( $R = 0.96$ ) between % high-spin and iron redox potential<sup>2</sup>. In fact, there is a clear relationship between shift to high-spin for the heme iron in microsomal P450 and rate of metabolism of benz-phetamine analogues<sup>59</sup>, thus indicating that substrate binding triggers the entire P450 catalytic cycle by modulating the spin-state equilibrium, lowering the P450 Fe<sup>3+</sup>/Fe<sup>2+</sup> redox potential and thus facilitating reduction of the heme iron from ferric to ferrous, such that dioxygen is able to bind to the reduced P450 and, consequently, become activated in order to oxygenate the substrate<sup>45,56</sup>. It is important, therefore, to appreciate why the P450 spin-state shift is essential for catalytic activity.


If one considers the thermodynamics of a typical P450 reaction, it is clear that the products are of lower energy than the reactants, but the uncatalyzed activation energy of the process (estimated to be 418–460 kJ.mol<sup>-1</sup>) ensures that the reaction is kinetically unfavourable at normal physiological temperatures<sup>60</sup>. However, the enzyme lowers this activation energy (to between 38–71 kJ.mol<sup>-1</sup>) by binding the substrate close to the heme group and by binding oxygen at the heme iron which, via the influence of the invariant cysteine, becomes activated following electron transfer<sup>2</sup>.

A key prerequisite for any organic reaction is that the reactants are in the same spin-state. Most organic compounds are in the singlet state, with paired electron spins, whereas molecular oxygen is in the triplet ground state with two unpaired electrons<sup>61</sup>. Consequently, the reaction between molecular dioxygen and organic substrates is termed spin-forbidden at normal temperatures<sup>61</sup>. Cytochrome P450 is able to catalyze this reaction, however, by altering the electronic state of oxygen, but the enzyme also makes use of the triplet ground state to ensure a high binding affinity between oxygen

and the heme iron which, in the presence of substrate, is also in a high-spin state (see Table 5). Furthermore, the oxygen binding affinity of hemoproteins in general is proportional to their iron redox potential<sup>62</sup> and, therefore, the substrate-dependent increase in E° for the Fe<sup>3+</sup>/Fe<sup>2+</sup> couple (i.e., it becomes less negative) is likely to be an additional factor in explaining the high oxygen binding affinity ( $K_D = 0.6 \mu\text{M}$  in CYP101) of substrate-bound reduced P450.

Consequently, the reaction between the heme iron and molecular oxygen in the P450 system is energetically favourable provided that the iron is in the high-spin state and is reduced from Fe<sup>3+</sup> to Fe<sup>2+</sup>, because this places an overall negative charge on the iron porphyrin system which is then transferred to the electron-deficient dioxygen molecule<sup>63</sup>. Moreover, the resulting activation of oxygen by the successive addition of two reducing equivalents (2H<sup>+</sup>, 2e<sup>-</sup>) gives rise to a singlet state peroxide species<sup>64</sup> that readily reacts with a singlet state substrate bound in the immediate vicinity of the heme iron-oxygen complex.

Energetically, the consecutive donation of two electrons to dioxygen brings about a lengthening (and, hence, weakening) of the oxygen-oxygen bond, as shown in Table 6. Therefore, the P450-catalyzed activation of oxygen can be represented as follows:



In this way superoxide is produced following the electron transfer from reduced (Fe<sup>2+</sup>) P450 to oxygen which is, in turn oxidized back to the Fe<sup>3+</sup> state<sup>56</sup>. The second reduction of P450 then facilitates the transfer of another electron from Fe<sup>2+</sup> to the superoxide anion such that the reactive peroxide species is formed<sup>64</sup>.

**TABLE 5**  
**Spin-State and Redox Potential (E°) in P450s<sup>8</sup>**

System	% High-Spin	E° (mV)
P450 <sub>cam</sub>	8	-303
P450 <sub>cam</sub> + camphor	94	-173
P450 <sub>rlm</sub>	10	-300
P450 <sub>rlm</sub> + hexobarbital	35	-237
P450 <sub>rlm</sub> + benzphetamine	38	-225

% high-spin = 0.61E° + 187.1 (±0.11); correlation coefficient = 0.96.

P450<sub>cam</sub> = camphor 5-exo monooxygenase from *pseudomonas putida*;

P450<sub>rlm</sub> = rat liver microsomal P450 isozymes.

Data compiled from Sligar et al., 1979<sup>58</sup>.

The likely stages in the P450 catalytic cycle are represented schematically in Fig. 4, which shows how the heme system in P450 is able to direct the course of the reaction during substrate binding, reduction, oxygenation, and rearrangement of the oxygenated complex leading to the formation of products<sup>2</sup>. It would appear that the P450 system achieves oxygen activation and mono-oxygenation of substrates in a carefully controlled, subtle fashion which has evolved over at least 2000 million years ago since the earth's atmosphere has contained free oxygen<sup>11</sup>. Consequently, the P450 tertiary structure would have evolved (possibly like the globins) to bind:

1. heme, via the invariant cysteine residue, together with the cooperation of at least two basic amino acids residues which form ion-pairs with the negatively charged propionate side chains on the heme moiety;
2. oxygen, via a deformation in the distal I helix which includes conserved glycine and threonine residues, together with a conserved acidic residue which acts cooperatively with the threonine to facilitate proton transfer to the activated oxygen moiety;
3. substrates, via the spatial orientation of key amino acid residues in the vicinity of the heme pocket which, although being otherwise essentially hydrophobic in nature, also enables the 'fine-tuning' of substrate regio-specificity in metabolism by genetically 'engineering' changes in active site residues; and
4. redox partners, for the consecutive input of two electrons via the placement of surface basic residues close to the proximal heme face, where a nearby hydrophobic channel facilitates proton transfer by solvating water molecules<sup>65</sup> via a conserved acidic residue downstream from the invariant cysteine ligand.

Evolutionary constraints would also have to provide a means of regulating all of these above features (namely, 1 to 4) by placing the enzyme complex in a membrane phospholipid environment<sup>45</sup>. Moreover, the porphyrin ring system coordinating iron in P450 (and other hemoproteins) places the elec-

tronic state of the heme unit in an ideal situation for the binding of small molecular ligands in an environment capable of being modulated by the presence (or absence) of water molecules, which affect both the spin- and redox-states of the iron atom<sup>5</sup>. Furthermore, the axial heme ligands alter the 3d orbital energy level splitting such that resulting electronic transitions effect a spectral change in the UV absorption maximum which, in the reduced P450 carbon monoxide complex, is characteristically situated at 450 nm<sup>66</sup>. This intense absorption in the electronic spectrum led, of course, to the original discovery of the enzyme, together with its name<sup>4</sup>. The various stages in the P450 cycle will now be reviewed with respect to substrate binding, oxygen activation, and insertion such that the mechanism of oxygenation can be appreciated.

## STAGES IN THE P450 CATALYTIC CYCLE AND MECHANISM OF OXYGENATION


As mentioned previously, P450 activity is regulated by substrate binding as this gives rise to a change in the hemoprotein from low-spin to high-spin ferriheme, which brings about a lowering of the  $\text{Fe}^{3+}/\text{Fe}^{2+}$  redox potential (moving from  $-303$  mV to  $-173$  mV in the bacterial system P450<sub>cam</sub>). This facilitates electron transfer from either a redoxin or reductase redox partner, which is of redox potential around 290 mV<sup>45</sup>. The change from low- to high-spin  $\text{Fe}^{3+}$  in P450 during substrate binding can be monitored spectroscopically<sup>52</sup> due to the fact that the alteration in electronic state of the heme iron affects the extent of 3d orbital splitting, leading to a shift in the Soret absorption maximum caused by a variation in electronic transitions within the cysteinyl-heme moiety (reviewed in Reference 2).

Due to the differences between the ionic radii of the high- and low-spin iron, especially that of the  $\text{Fe}^{3+}$  state, the iron atom will be expected to move out of the plane of the porphyrin ring in high-spin heme iron; this has been observed in the

TABLE 6  
Data for Oxygen Species<sup>2</sup>

Species	Bond Length (Å)	Bond Energy (kJ.mol <sup>-1</sup> )	O–O Stretch (cm <sup>-1</sup> )
O <sub>2</sub>	1.21	497	1555
O <sub>2</sub> <sup>-</sup>	1.33	276	1107
O <sub>2</sub> <sup>2-</sup>	1.49	146	850

NB: The uncatalyzed activation energy for typical P450-mediated reactions lies in the range 418–460 kJ.mol<sup>-1</sup> which is close to the bond energy value for molecular oxygen.



**FIGURE 4.** A proposed scheme for the P450 catalytic cycle (adapted from Reference 2). RH = hydrocarbon substrate; ROH = oxygenated metabolite; HS = high-spin; LS = low-spin.

crystal structure of substrate-bound P450<sub>cam</sub><sup>67</sup>. Table 7 compares the iron-sulphur and iron-nitrogen distances in substrate-bound and substrate-free P450<sub>cam</sub> (CYP101) where there is a change from high-spin to low-spin ferric iron, respectively. The iron atom lies about 0.4 Å out of the porphyrin ring plane, and the difference between high- and low-spin Fe<sup>3+</sup> ionic radii is sufficient to account for the movement of iron toward the cysteinate sulphur atom in substrate-bound P450<sub>cam</sub> (see Table 7). It is likely that substrate binding brings about a conformational change in the P450 which is associated with substrate-induced desolvation of the heme environment<sup>65</sup> and movement of the iron atom out of the plane of the porphyrin ring. Although there are few differences in substrate-bound and substrate-free P450<sub>cam</sub><sup>6,67</sup>, comparison between substrate-bound and substrate-free P450<sub>bms</sub> (CYP102) shows that significant conformational changes occur for the larger substrate, palmitoleic acid<sup>68,69</sup>.

Following reduction of the substrate-bound P450 complex, there is evidence to suggest that the substrate moves closer to the heme iron<sup>70</sup> on the basis of NMR paramagnetic shift data<sup>71</sup>. It is possible that the subsequent increased negative charge on the heme moiety brings about an attraction of the substrate hydrogen atoms, which bear a partial positive charge, and it should be recalled that oxygenation usually proceeds via proton abstraction of the substrate<sup>63</sup>. The rate of initial reduction is substantially faster than the second reduction, which is generally regarded as being rate-limiting in both bacterial and microsomal systems<sup>56</sup>. The first reduction is probably triggered by the conformational change in the P450 apoprotein which accompanies substrate binding and, in the microsomal system, may relate to a reorientation of the P450 molecule within the membrane phospholipid such that interaction with reductase is facilitated<sup>72</sup>.

When in the Fe<sup>2+</sup> state, oxygen binding occurs due to the higher oxygen affinity for the ferrous high-spin state, and this could proceed via spin-spin coupling between triplet ground

state dioxygen (with two unpaired electrons) and high-spin Fe<sup>2+</sup> which contains four unpaired electrons (reviewed in Reference 2). As it is known that the interaction energy between two spin-free species is proportional to the product of their spin quantum numbers, the strong binding between reduced P450 and molecular dioxygen may be at least partially determined by the spin-pairing interaction, although the electron-deficient oxygen species will be attracted to the electron-rich Fe<sup>2+</sup> P450 and this could represent the dominant force in the oxygen binding process<sup>5</sup>. The ferrous iron in P450 changes to low-spin when oxygen is bound to the distal heme face, and the local environment of the P450 active site favours the electron transfer of Fe<sup>2+</sup> to oxygen, giving rise to the Fe<sup>3+</sup> O<sub>2</sub><sup>-</sup> state<sup>56</sup>. It is thought that the presence of protonated basic amino acid residues, and the likelihood of proton transfer pathway<sup>65</sup> via hydrogen-bonded conduits within the apoprotein, will lead to protonation of the resultant superoxide anion according to the process:



which possesses a high equilibrium constant ( $K = 10^{12}$ ) such that the protonated superoxy species is favoured at normal temperature<sup>73</sup>. This, in turn, would have the effect of promoting the formation of iron(III)superoxide from the initial iron(II)dioxygen complex in P450<sup>2,56</sup>.

The presence of superoxide in the P450<sub>cam</sub> system has been directly observed under catalytic conditions using resonance Raman spectroscopy<sup>74</sup>. Table 6 indicates that the O-O stretching frequency is characteristic of the dioxygen species electronic state, and the oxygen-oxygen stretch in P450<sub>cam</sub> at 1141 cm<sup>-1</sup> appears to confirm the formation of an iron-bound superoxide<sup>74</sup>. In fact, the addition of superoxide to substrate-bound reduced P450<sub>cam</sub> is catalytically competent, and indicates that the initial Fe<sup>2+</sup>O<sub>2</sub><sup>-</sup> complex may also undergo electron transfer to form an iron(III)peroxide species<sup>75</sup>.

**TABLE 7**  
**Interatomic Distances in the P450<sub>cam</sub> Heme Group and Fe<sup>3+</sup> Ionic Radii (Å)**

Atomic Distance	P450 <sub>cam</sub> (HS)	P450 <sub>cam</sub> (LS)
Fe-S	2.177	2.254
Fe-N	2.034	2.024
Fe-C <sub>t</sub>	0.433	0.0
Fe <sup>3+</sup> radius	0.64	0.55

C<sub>t</sub> is the centre of the porphyrin ring plane.

The shortening of Fe-S bond length in substrate-bound P450<sub>cam</sub> (0.08 Å) is about the same as the difference between the ionic radii (0.09 Å).

*References:* Crystal structure of substrate-bound P450<sub>cam</sub><sup>67</sup>; crystal structure of substrate-free P450<sub>cam</sub><sup>6</sup>; ionic radii of high-spin and low-spin Fe<sup>3+</sup><sup>77</sup>.


This finding may provide a clue to the final stages in the P450 catalytic cycle where the oxygenated complex is reduced via a second electron transfer from the redox partner (reviewed in Reference 56). Based on the assumption that the initial reduced P450-dioxygen adduct tends to form an iron(III) superoxide via the process:



then the second reduction would give rise to iron(II)O<sub>2</sub><sup>-</sup> by the input of another electron to iron(III)O<sub>2</sub><sup>-</sup><sup>63</sup>. The ferrous-superoxide complex is analogous to the situation produced artificially by the addition of superoxide to reduced P450<sub>cam</sub><sup>75</sup> and it is possible that, for the same reasons outlined previously for the iron(II)O<sub>2</sub><sup>-</sup> complex, there is a conversion to an iron(III)peroxide according to the process:



Ferric-bound peroxide is highly reactive<sup>64</sup> and then breaks down, possibly under the influence of solvated protons in the heme environment, to oxygenate the bound substrate; this process, which is not fully understood, may involve the transient formation of a bare oxygen atom<sup>4</sup>, probably produced via the decomposition of heme-bound hydrogen peroxide according to the reaction:



This sequence of stages is consistent with the production of water, which is also formed in P450 reactions, together with

the mono-oxygenated metabolite resulting from single oxygen atom insertion into the substrate molecule<sup>63</sup>. It can be appreciated that the catalytic cycle (as outlined above) returns the P450 to its low-spin ferric resting state after having undergone the electronic changes described previously. There is clear experimental evidence for each intermediate proposed in the various stages of the P450-mediated oxygenation of organic substrates, apart from the high reactive single oxygen atom, although its presence has been reported in model systems<sup>76</sup>. However, it is apparent that the binding of substrate triggers the entire P450 catalytic cycle by bringing about a series of carefully controlled changes in the P450 system which leads to oxygen binding, activation and single oxygen insertion into the substrate, thus forming the mono-oxygenated product with the concomitant production of a water molecule (reviewed in Reference 2). Substrate binding appears to affect the haem iron spin-state equilibrium where, in general, there is a substrate-induced change from low-spin to high-spin iron (reviewed in Reference 2) and data from iron complexes<sup>77</sup> indicates that the iron is likely to move out of the heme plane, as is observed in the crystal state<sup>67</sup>. Moreover, substrate binding alters the hemoprotein redox potential, which may be related to the extent of heme exposure<sup>78</sup> and it is also possible that this has a bearing on the rate of substrate turnover. Table 8 provides details of the catalytic turnovers in selected P450 systems, with the CYP102 reaction proceeding at a rate close to the diffusion-controlled limit for an enzyme catalyzed reaction<sup>7</sup>.

## CONCLUSIONS

P450 enzymes play an important role in the metabolism of a vast number and variety of both endogenous and exogenous chemicals<sup>46</sup>. Although their general reaction of mono-oxygen-

ation is common to most P450 functions, they can catalyze the oxidative metabolism of virtually every class of organic chemical due to certain key complementary amino acid residue interactions within the active sites of different P450s<sup>49</sup> which govern their various substrate specificities, notwithstanding some degree of overlap in the mammalian P450s associated with xenobiotic metabolism.

The major roles of mammalian P450s include the following:

1. steroid hormone biosynthesis (CYP11, CYP17, CYP19, and CYP21);
2. activation of chemical carcinogens (CYP1 and CYP2E);
3. detoxication of foreign compounds (CYP1, CYP2, and CYP3);
4. metabolism of fatty acids, prostanoids, and eicosanoids (CYP4); and
5. development and maintenance of sex characteristics (CYP1, CYP2, and CYP3).

Other P450s present in fungi (CYP51-62), plants (CYP71-92), and bacteria (CYP101-118) are associated with the metabolism of natural products such as lanosterol (CYP51), citral (CYP71A5), and erythromycin (CYP107 and CYP113). Over 1200 P450 gene sequences have been determined from over 85 eukaryotic species and in excess of 20 prokaryotic species<sup>1</sup>. However, the three-dimensional structures of only 7 P450s have been characterized by X-ray crystallography and all of these are from bacterial sources<sup>6,67,68,69,70</sup>. Nevertheless, the tertiary fold is generally well conserved for all of these crystal structures despite the fact that the substrates vary from camphor (CYP101), palmitoleic acid (CYP102),  $\alpha$ -terpineol (CYP108), and erythromycin (CYP107). Comparison of P450 gene and protein sequences indicate that the entire gene superfamily evolved over a period of at least 2000 million years, and construction of the P450 phylogenetic tree provides a number of interesting concordances with the generally accepted time-course for the evolution of biological systems on earth<sup>11</sup>. There is evidence to suggest that the gradual rise of

atmospheric oxygen levels since the atmosphere changed from being reducing to oxidizing in nature over the last 2000 years (brought about by the advent of photosynthesizing bacterial species), played a key role<sup>18,25,26</sup> in the evolution of eukaryotic species, including: vertebrates, mammalia, primates, and, eventually, *Homo sapiens*. However, the possibility of variable rates of P450 evolution over time can lead to difficulties in making accurate comparisons with biological development over large time periods.

In addition to the likelihood that the increase in atmospheric oxygenation drives evolutionary change, where the P450 isozymes have played a significant role in both steroid hormone biosynthesis and xenobiotic metabolism, for example, it is possible that the pattern of global mass extinctions over geological time can be linked with terrestrial cycles of supercontinental fission and fusion events, together with planetary orbital periods and galactic rotation of the solar system<sup>27,29,30</sup>. Among other global changes produced via these cyclical effects, the rise in eustatic sea level appear to coincide with a number of major marine extinctions over the past 500 million years or more<sup>29</sup>. Consequently, a combination of first and second order terrestrial cycles probably accounts for the majority of global biological extinctions, which led to the dominance of mammalian species in recent geological time (i.e., since the last mass extinction occurred 65 million years ago). The current complement of drug-metabolizing P450s in man and other mammalian species may have originally developed as a response to plant toxins biosynthesized to deter animal predators when land colonization began around 400 million years ago<sup>8,10</sup>. It is, therefore, a fortunate circumstance that modern drugs have been designed largely from plant alkaloid templates, because the necessary detoxifying enzymes are already present for drug metabolism in man.

There are exciting possibilities for utilizing a bacterial P450 such as CYP102 in biotechnological applications such as bioremediation and biodegradation<sup>79</sup>. The CYP101 enzyme has already been employed in similar ways<sup>80</sup> for catalysing the aromatic hydroxylation of diphenylmethane, whereas its usual function is camphor-5-exo hydroxylation. Consequently, only

**TABLE 8**  
**Catalytic Turnover Numbers for Different P450s**

P450	Turnover (min <sup>-1</sup> )	Substrate	Type	Redox Partner	Class of P450
CYP2B4	29	Benzphetamine	Microsomal	Reductase	II (E)*
CYP101	1900	Camphor	Bacterial	Redoxin	I (B)
CYP102	4600	Lauric acid	Bacterial	Linked reductase	II (E)

\* E = eukaryotic; B = bacterial.

References: information compiled from References 2, 48, and 56.

a single mutation can give rise to a genetically engineered enzyme with markedly different catalytic selectivity<sup>80</sup>. Applying this principle to CYP102 would be advantageous as this fused enzyme exhibits catalytic self-sufficiency coupled with a significantly higher turnover rate<sup>57</sup>.

## ACKNOWLEDGEMENTS

The financial support of GlaxoWellcome Research & Development Limited, Merck, Sharp & Dohme Limited, the European Commission Biomed II programme (EUROCYP) and the University of Surrey Foundation Fund is gratefully acknowledged by one of us (DFVL).

## REFERENCES

- Nelson, D.R., Koymans, L., Kamataki, T., Stegeman, J.J., Feyereisen, R., Waxman, D.J., Waterman, M.R., Gotoh, O., Coon, M.J., Estabrook, R.W., Gunsalus, I.C., and Nebert, D.W. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, *Pharmacogenetics* **6**, 1-42. The following website provides more recent information: [http://drnelson.utmen.edu/Cytochrome P450/html](http://drnelson.utmen.edu/Cytochrome%20P450/html).
- Lewis, D.F.V. (1996) *Cytochromes P450: Structure, Function and Mechanism*. Taylor & Francis, London.
- Lewis, D.F.V. (1997) Sex and drugs and P450. *Chem. Ind.* Oct. 20, 381-384.
- Guengerich, F.P. (1993) Cytochrome P450 enzymes. *Am. Sci.* **81**, 440-447.
- Frausto da Silva, J.J. and Williams, R.J.P. (1991) *The Biological Chemistry of the Elements*. Clarendon Press, Oxford.
- Poulos, T.L., Finzel, B.C., and Howard, A.J. (1986) Crystal structure of substrate-free *Pseudomonas putida* P450. *Biochemistry* **25**, 5314-5322.
- Lehninger, A.L., Nelson, D.L., and Cox, M.M. (1993) *Principles of Biochemistry, Second Edition*. Worth, New York.
- Gonzalez, F.J. and Nebert, D.W. (1990) Evolution of the P450 gene superfamily. *Trends Genet.* **6**, 182-186.
- Nebert, D.W. and Nelson, D.R. (1991) P450 gene nomenclature based on evolution. *Methods Enzymol.* **206**, 3-11.
- Nebert, D.W. and Gonzalez, F.J. (1990) The P450 gene superfamily. *Front. Biotransform.* **2**, 35-61.
- Lewis, D.F.V., Watson, E., and Lake, B.G. (1998) Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. *Mutat. Res.* **410**, 245-270.
- Cloud, P. (1976) Beginnings of biospheric evolution and their biogeochemical consequences. *Paleobiology* **2**, 351-387.
- Doolittle, R.F., Feng, D.-F., Tsang, S., Cho., G., and Little, E. (1996) Determining divergence times of the major kingdoms of living organisms with a protein clock. *Science* **271**, 470-477.
- Nelson, D.R., Kamataki, T., Waxman, D.J., Guengerich, F.P., Estabrook, R.W., Feyereisen, R., Gonzalez, F.J., Coon, M.J., Gunsalus, I.C., Gotoh, O., Okuda, K., and Nebert, D.W. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. *DNA Cell Biol.* **12**, 1-51.
- Lovelock, J.E. (1987) *Gaia*. Oxford University Press, Oxford.
- Lovelock, J.E. (1991) *The Ages of Gaia*. Oxford University Press, Oxford.
- Margulis, L. and Sagan, D. (1995) *What is Life?* Weidenfeld & Nicolson, London.
- Canfield, D.E. and Teske, A. (1996) Late proterozoic rise in atmospheric oxygen concentration inferred from phylogenetic and sulphur-isotope studies. *Nature* **382**, 127-132.
- Bryant, C. (1993) Doing without oxygen. *The Biologist* **40**, 58-61.
- Yang, D., Oyaizu, Y., Oyaizu, H., Olsen, G.J., and Woese, C.R. (1985) Mitochondrial origins. *Proc. Natl. Acad. Sci. U.S.A.* **82**, 4443-4447.
- Martin, A.P. and Palumbi, S.R. (1993) Body size, metabolic rate, generation time and the molecular clock. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 4087-4091.
- Fujii-Kuriyama, Y., Kimura, H., Higashi, Y., Sogawa, K., Inoue, H., Shimizu, T., Hatano, M., and Gotoh, O. (1989) Structural characteristics of cytochrome P450 molecules. In *Cytochrome P450-Biochemistry and Biophysics*. Schuster, I., Ed. Taylor & Francis, London, pp. 455-463.
- Maurel, P. (1996) The CYP3 family. In *Cytochromes P450-Metabolic and Toxicological Aspects*. Ioannides, C., Ed. CRC Press, Boca Raton, FL. Chap.11, pp. 241-270.
- Lake, B.G. and Lewis, D.F.V. (1996) The CYP4 family. In *Cytochromes P450-Metabolic and Toxicological Aspects*. Ioannides, C., Ed. CRC Press, Boca Raton, FL. Chap.11, 271-297.
- Knoll, A.H. (1992) The early evolution of eukaryotes: a geological perspective. *Science* **256**, 622-627.
- Knoll, A.H. (1996) Breathing room for early animals. *Nature* **382**, 111-112.
- Ridley, M. (1996) *Evolution (Second Edition)*. Blackwell, Cambridge, MA.
- Windley, B.F. (1995) *The Evolving Continents (Third Edition)*. Wiley, New York.
- Doyle, P., Bennett, M.R., and Baxter, A.N. (1994) *The Key to Earth History*. Wiley, New York.
- Hedges, S.B., Parker, P.H., Sibley, C.G., and Kumar, S. (1996) Continental breakup and the ordinal diversification of birds and mammals. *Nature* **381**, 226-229.
- Nelson, D.R. and Strobel, H.W. (1987) Evolution of cytochrome P450 proteins. *Mol. Biol. Evol.* **4**, 572-593.
- Zimniak, P. and Waxman, D.J. (1993) Liver cytochrome P450 metabolism of endogenous steroid hormones, bile acids and fatty acids. In *Cytochrome P450*. Schenkman, J.B. and Griem, H., Eds. Springer-Verlag, Berlin, pp. 123-144.
- Warner, M., Stromstedt, M., Wyss, A., Yoshida, S., and Gustafsson, J.A. (1994) Induction of brain P450 by solvents and pharmaceuticals. In *Cytochrome P450-Biochemistry, Bio-*

- physics and Molecular Biology*. Lechner, M.C., Ed. Libbey, Paris, pp. 81-88.
34. Ronis, M.J.J., Lindros, K.O., and Ingelman-Sundberg, M. (1996) The CYP2E subfamily. In *Cytochromes P450-Metabolic and Toxicological Aspects*. Ioannides, C., Ed. CRC Press, Boca Raton, FL. Chap.9, pp. 211-239.
  35. Katagiri, K. and Hayashi, S.-i. (1996) The CYP1 family. In *Cytochromes P450-metabolic and Toxicological Aspects*. Ioannides, C., Ed. CRC Press, Boca Raton, FL. Chap. 4, pp. 77-97.
  36. Horn, E.P., Tucker, M.A., Lambert, G., Silverman, D., Zametkin, D., Sinha, R., Hartge, T., Landi, M.T., and Caporaso, N.E. (1995) A study of the gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. *Cancer Epidemiol. Biomarkers Prevent.* **4**, 529-533.
  37. Nebert, D.W., Nelson, D.R., Coon, M.J., Estabrook, R.W., Feyereisen, R., Fujii-Kuriyama, Y., Gonzalez, F.J., Guengerich, F.P., Gunsalus, I.C., Johnson, E.F., Loper, J.C., Sato, R., Waterman, M.R., and Waxman, D.J. (1991) The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature, *DNA Cell Biol.* **10**, 1-14.
  38. Gonzalez, F.J. (1988) The molecular biology of cytochrome P450s. *Pharmacol. Rev.* **40**, 243-288.
  39. Lewis, D.F.V. and Lake, B.G. (1995) Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. *Xenobiotica* **25**, 585-598.
  40. Lewis, D.F.V. and Lake, B.G. (1996) Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. *Xenobiotica* **26**, 723-753.
  41. Gould, S.J. (1993) *The Book of Life*. Hutchinson, London.
  42. Rendic, S. and Di Carlo, F.J. (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. *Drug Metab Rev.* **29**, 413-580.
  43. Crawford, M. and Marsh, D. (1989) *The Driving Force: Food in Evolution and the Future*. Heinemann, London.
  44. Nebert, D.W. (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? *Am. J. Hum. Genet.* **60**, 265-271.
  45. Bernhardt, R. (1995) Cytochrome P450: structure, function and generation of reactive oxygen species. *Rev. Physiol. Biochem. Pharmacol.* **127**, 137-221.
  46. Porter, T.D. and Coon, M.J. (1991) Cytochrome P450: multiplicity of isoforms, substrates and catalytic and regulatory mechanisms. *J. Biol. Chem.* **266**, 13469-13472.
  47. Guengerich, F.P. (1992) Metabolic activation of carcinogens. *Pharmacol. Ther.* **54**, 17-61.
  48. Degtyarenko, K.N. and Archakov, A.I. (1993) Molecular evolution of P450 superfamily and P450-containing mono-oxygenase systems. *FEBS Lett.* **332**, 1-8.
  49. Smith, D.A., Ackland, M.J., and Jones, B.C. (1997) Properties of cytochrome P450 isoenzymes and their substrate. Part 2. Properties of cytochrome P450 substrates. *Drug Discovery Today* **2**, 479-486.
  50. Bachmann, K.A. (1996) The cytochrome P450 enzymes of hepatic drug metabolism: how are their activities assessed *in vivo*, and what is their clinical significance? *Am J. Ther.* **3**, 150-171.
  51. Hawkins, B.K. and Dawson, J.H. (1992) Oxygen activation by heme-containing mono-oxygenases: cytochrome P450 and secondary amine mono-oxygenase. Active site structures and mechanism of action. *Front. Biotransform.* **7**, 216-278.
  52. Sligar, S.G. (1976) Coupling of spin, substrate and redox equilibria in cytochrome P450. *Biochemistry* **15**, 5399-5406.
  53. Degtyarenko, K.N. (1995) Structural domains of P450-containing monooxygenase systems. *Protein Eng.* **8**, 737-747.
  54. Woese, C.R. (1987) Bacterial evolution. *Microbiol. Rev.* **51**, 221-271.
  55. Wheelis, M.L., Kandler, O., and Woese, C.R. (1992) On the nature of global classification. *Proc. Natl. Acad. Sci. U.S.A.* **89**, 2930-2934.
  56. Archakov, A.I. and Bachmanova, G.I. (1990) *Cytochrome P-450 and Active Oxygen*. Taylor & Francis, London.
  57. Fulco, A.J. (1991) P450<sub>BM-3</sub> and other inducible bacterial P450 cytochromes: biochemistry and regulation. *Annu. Rev. Pharmacol. Toxicol.* **31**, 177-203.
  58. Sligar, S.G., Cinti, D.L., Gibson, G.G., and Schenkman, J.B. (1979) Spin state control of the hepatic cytochrome P450 redox potential *Biochem. Biophys. Res. Commun.* **90**, 925-932.
  59. Blanck, J., Rein, H., Sommer, M., Ristau, O., Smettan, G., and Ruckpaul, K. (1983) Correlation between spin equilibrium shift, reduction rate and N-demethylation activity in liver microsomal cytochrome P450 and a series of benzphetamine analogues as substrates. *Biochem. Pharmacol.* **32**, 1683-1688.
  60. Ruckpaul, K., Rein, H. and Blanck, J. (1989) Regulation mechanisms of the activity of the hepatic endoplasmic cytochrome P450. *Front. Biotransform.* **1**, 1-65.
  61. Hill, H.A.O. (1978) The superoxide ion and the toxicity of molecular oxygen. In *New Trends in Bio-Inorganic Chemistry*. Williams, R.J.P. and de Silva, J.J.R.F., Eds. Academic Press, New York, Ch.6, 173-208.
  62. Addison, A.W. and Burman, S. (1985) Ligand-dependent redox chemistry of *glycera dibranchiata* hemoglobin. *Biochim. Biophys. Acta*, **828**, 362-368.
  63. Kaim, W. and Schwederski, B. (1994) *Bioinorganic Chemistry: Inorganic Elements in the Chemistry of Life*, Wiley, New York.
  64. Pratt, J.M., Ridd, T.I., and King, L.J. (1995) Activation of H<sub>2</sub>O<sub>2</sub> by P450: evidence that the hydroxylating intermediate is iron-coordinated H<sub>2</sub>O<sub>2</sub> and not the ferryl FeO<sup>3+</sup> complex. *Chem. Commun.*, 2297-2298.
  65. Oprea, T.L., Hummer, G., and Garcia, A.E. (1997) Identification of a functional water channel in cytochrome P450 enzymes. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 2133-2138.
  66. Sato, R. and Omura, T. (1976) *Cytochrome P450*, Academic Press, New York.
  67. Poulos, T.L., Finzel, B.C., and Howard, A.J. (1987) High-resolution crystal structure of cytochrome P450<sub>cam</sub>. *J. Mol. Biol.* **195**, 687-700.

68. Ravichandran, K.G., Boddupalli, S.S., Hasemann, C.A., Peterson, J.A., and Deisenhofer, J. (1993) Crystal structure of hemoprotein domain of P450<sub>BM-3</sub>, a prototype for microsomal P450s. *Science*, **261**, 731-736.
69. Li, H. and Poulos, T.L. (1997) The structure of the cytochrome P450<sub>BM-3</sub> haem domain complexed with the fatty acid substrate, palmitoleic acid. *Nature Struct. Biol.* **4**, 140-145.
70. Poulos, T.L., (1996) Ligands and electrons and haem proteins. *Nature Struct. Biol.*, **3**, 401-403.
71. Modi, S. Sutcliffe, M.J., Primrose, W.U., Lian, L.-Y., and Roberts, G.C.K. (1996) The catalytic mechanism of cytochrome P450<sub>BM-3</sub> involves a 6Å movement of the bound substrate on reduction, *Nature Struct. Biol.* **3**, 414-417.
72. Finch, S.A.E. and Stier, A. (1991) Rotational diffusion of Homo- and hetero oligomers of cytochrome P450, the functional significance of cooperativity and the membrane structure, *Front. Biotransform.* **5**, 34-71.
73. Chin, D.-H., Chiericato, G., Nanni, E.J., and Sawyer, D.T. (1982) Proton-induced disproportionation of super-oxide ion in aprotic media, *J. Am. Chem. Soc.* **104**, 1296-1299.
74. Egawa, T., Ogura, T., Makino, R., Ishimura, Y., and Kitagawa, T. (1991) Observation of the O-O stretching Raman band for cytochrome P450<sub>cam</sub> under catalytic conditions, *J. Biol. Chem.* **266**, 10246-10248.
75. Kobayashi, K., Iwamoto, T., and Honda, K. (1994) Spectral intermediate in the reaction of ferrous cytochrome P450<sub>cam</sub> with superoxide anion, *Biochem. Biophys. Res. Commun.* **201**, 1348-1355.
76. Sugimoto, H., Tung, H.-C., and Sawyer, D.T. (1988) Formation, characterization and reactivity of the oxene adduct of tetrakis(2,6-dichlorophenyl)-porphinato.iron(III) perchlorate in acetonitrile: model for the reactive intermediate of cytochrome P450, *J. Am. Chem. Soc.* **110**, 2465-2470.
77. Shannon, R.D. and Prewitt, L.T. (1970) Revised values of effective ionic radii, *Acta Crystallogr.* **B26**, 1046-1048.
78. Stellwagen, E. (1978) Haem exposure as the determinate of oxidation-reduction potential of haem proteins, *Nature*, **275**, 73-74.
79. Guengerich, F.P. (1995) Cytochrome P450 proteins and potential utilization in biodegradation, *Environ. Health Perspect.* **102**, Suppl. 5, 25-28.
80. Fowler, S.M., England, P.A., Westlake, A.C.G., Rouch, D.R., Nickerson, D.P., Blunt, C., Braybrook, D., West, S., Wong, L.-L., and Flitsch, S.L. (1994) Cytochrome P450<sub>cam</sub> monooxygenase can be redesigned to catalyze the regioselective aromatic hydroxylation of diphenylmethane, *Chem. Commun.* 2761–2762.

---

**This article should be referenced as follows:**

Lewis, D.F.V. (2001) Cytochromes P450, oxygen, and evolution. *TheScientificWorld* 1, 151–167.

---

Received:	December	29, 2000
Revised:	March	15, 2001
Accepted:	March	16, 2001
Published:	April	19, 2001



**Hindawi**

Submit your manuscripts at  
<http://www.hindawi.com>

